Michael A Davies Selected Research

IACS-010759

1/2020	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
11/2019	Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo.
1/2019	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael A Davies Research Topics

Disease

156	Melanoma (Melanoma, Malignant) 09/2022 - 08/2009
120	Neoplasms (Cancer) 12/2022 - 04/2002
37	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2009
20	Brain Neoplasms (Brain Tumor) 01/2022 - 04/2011
10	Disease Progression 01/2020 - 11/2012
8	Breast Neoplasms (Breast Cancer) 01/2020 - 07/2009
3	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2012
3	Enterocolitis 01/2022 - 10/2018
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 11/2016
3	Uveal melanoma 01/2020 - 08/2012
3	Leukemia 11/2019 - 05/2014
2	Colitis 01/2022 - 10/2018
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 11/2016
2	Carcinogenesis 01/2018 - 07/2009
2	Headache (Headaches) 01/2018 - 01/2017
2	Fever (Fevers) 01/2018 - 01/2017
2	Exanthema (Rash) 01/2018 - 12/2017
2	Thrombocytopenia (Thrombopenia) 01/2017 - 02/2012
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2017 - 08/2012
1	Arthritis (Polyarthritis) 12/2022

Drug/Important Bio-Agent (IBA)

33	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2009
29	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 11/2010
26	Biomarkers (Surrogate Marker)IBA 12/2022 - 06/2002
22	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2016
15	trametinibIBA 01/2021 - 08/2012
14	dabrafenibIBA 01/2021 - 11/2012
13	Pharmaceutical PreparationsIBA 01/2021 - 02/2010
11	IpilimumabIBA 01/2022 - 11/2012
11	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2016
9	VemurafenibIBA 01/2018 - 10/2012
8	Phosphotransferases (Kinase)IBA 01/2021 - 07/2009
7	AntibodiesIBA 01/2022 - 12/2010
7	Biological ProductsIBA 01/2021 - 01/2014
7	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2009
6	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 08/2012
6	Messenger RNA (mRNA)IBA 10/2021 - 01/2014
6	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2021 - 04/2002
5	Small Interfering RNA (siRNA)IBA 06/2016 - 11/2010
4	NivolumabIBA 01/2022 - 01/2018
4	Interleukin-2 (IL2)IBA 01/2018 - 01/2012
4	Dacarbazine (DIC)FDA LinkGeneric 01/2018 - 02/2013
4	CytokinesIBA 11/2016 - 05/2012
4	AZD 6244IBA 12/2014 - 11/2010
3	pembrolizumabIBA 01/2022 - 10/2016
3	MicroRNAs (MicroRNA)IBA 01/2022 - 08/2017
3	CTLA-4 AntigenIBA 01/2022 - 01/2017
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2021 - 03/2010
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 03/2010
3	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 01/2021 - 11/2014
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2020 - 01/2016
3	IACS-010759IBA 01/2020 - 01/2019
3	Estrogen ReceptorsIBA 01/2020 - 01/2016
3	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2019 - 01/2017
3	EnzymesIBA 12/2018 - 06/2010
3	SteroidsIBA 10/2018 - 01/2017
3	Neuregulin-1 (Neuregulin 1)IBA 10/2018 - 08/2014
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2018 - 11/2010
3	Mechanistic Target of Rapamycin Complex 1IBA 01/2018 - 12/2014
3	LigandsIBA 12/2017 - 10/2012
3	Temozolomide (Temodar)FDA LinkGeneric 12/2016 - 08/2014
3	PLX 4720IBA 08/2014 - 01/2013
3	Mitogen-Activated Protein KinasesIBA 05/2014 - 11/2010
2	Long Noncoding RNAIBA 01/2022 - 06/2016
2	cyclopropapyrroloindoleIBA 01/2022 - 10/2018
2	Imatinib Mesylate (Gleevec)FDA Link 12/2021 - 08/2009
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 11/2021 - 03/2010
2	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 09/2010
2	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 12/2017
2	Amino Acids FDA Link 01/2020 - 09/2014
2	Infliximab (Remicade)FDA Link 04/2019 - 10/2018
2	palbociclibIBA 01/2019 - 01/2016
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019 - 11/2016
2	130-nm albumin-bound paclitaxelIBA 11/2018 - 08/2014
2	ParaffinIBA 01/2018 - 03/2015
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2018 - 04/2002
2	Protein Isoforms (Isoforms)IBA 01/2018 - 01/2017
2	Proto-Oncogene Proteins B-rafIBA 01/2018 - 09/2013
2	Formaldehyde (Formol)FDA Link 01/2018 - 03/2015
2	AntigensIBA 10/2017 - 06/2015
2	MitogensIBA 02/2016 - 08/2012
2	NucleotidesIBA 06/2015 - 09/2014
2	Cisplatin (Platino)FDA LinkGeneric 08/2014 - 03/2010
2	temsirolimus FDA Link 02/2013 - 02/2012
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 08/2012 - 02/2012
2	lysophosphatidic acidIBA 05/2012 - 06/2010
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2010 - 08/2009
1	IntegrinsIBA 01/2022
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 01/2022

Therapy/Procedure

103	Therapeutics 12/2022 - 07/2009
31	Immunotherapy 01/2022 - 12/2012
10	Drug Therapy (Chemotherapy) 01/2022 - 03/2010
3	Radiotherapy 09/2022 - 01/2019
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 12/2012
3	Neoadjuvant Therapy 01/2021 - 06/2015
3	Precision Medicine 01/2017 - 01/2016
2	Lymph Node Excision (Lymph Node Dissection) 07/2021 - 11/2014
2	Aftercare (After-Treatment) 12/2020 - 08/2014
1	Immunomodulation 12/2022
1	Ostomy 09/2022